Screener
Jade Biosciences JBIO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
FAQ
- What is Jade Biosciences's EPS (diluted)?
- Jade Biosciences (JBIO) reported EPS (diluted) of -$0.57 in Q1 2026.
- How has Jade Biosciences's EPS (diluted) changed year-over-year?
- Jade Biosciences's EPS (diluted) increased by 95.3% year-over-year, from -$12.10 to -$0.57.
- What is the long-term trend for Jade Biosciences's EPS (diluted)?
- Over 3 years (2022 to 2025), Jade Biosciences's EPS (diluted) has grown at a 85.9% compound annual growth rate (CAGR), from -$2.11 to -$13.55.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Jade Biosciences's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude